Evidence map›Paper›PMID 17109408›Full record

ArticleProteins2007

How a small change in retinal leads to G-protein activation: initial events suggested by molecular dynamics calculations.

Paul S Crozier, Mark J Stevens, Thomas B Woolf

Open access · greenAbstract read
In one paragraph

Article in Proteins, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Understanding functional residues of the cannabinoid CB1.Current topics in medicinal chemistry · 2010
    Review
  6. Article
  7. Atomistic insights into rhodopsin activation from a dynamic model.Journal of the American Chemical Society · 2008
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Paul S CrozierSandia National Laboratories, MS 1322, Albuquerque, New Mexico 87185-1322, USA. pscrozi@sandia.gov
Mark J Stevens
Thomas B Woolf
Sandia National Laboratories California · USJohns Hopkins Medicine · US

Funding

Structure and Affinity: Computing FABP-Lipid SelectivityR01GM064746 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI WOOLF, THOMAS B · 2003 to 2006
$1.1M
NIGMS NIH HHS R01 GM064746
6 · The paper itself

Abstract

Rhodopsin is the prototypical G-protein coupled receptor, coupling light activation with high efficiency to signaling molecules. The dark-state X-ray structures of the protein provide a starting point for consideration of the relaxation from initial light activation to conformational changes that may lead to signaling. In this study we create an energetically unstable retinal in the light activated state and then use molecular dynamics simulations to examine the types of compensation, relaxation, and conformational changes that occur following the cis-trans light activation. The results suggest that changes occur throughout the protein, with changes in the orientation of Helices 5 and 6, a closer interaction between Ala 169 on Helix 4 and retinal, and a shift in the Schiff base counterion that also reflects changes in sidechain interactions with the retinal. Taken together, the simulation is suggestive of the types of changes that lead from local conformational change to light-activated signaling in this prototypical system.

Indexed as

AlanineAnimalsBinding SitesCattleComputer SimulationGTP-Binding ProteinsKineticsMagnetic Resonance SpectroscopyProtein ConformationRetinaldehydeRhodopsinX-Ray DiffractionAlanineGTP-Binding ProteinsRetinaldehydeRhodopsin

Identifiers

PMID17109408
PMCPMC2848121
OpenAlexW2114092722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.